HAMAM

Despite tremendous advances in modern imaging technology, both early detection and accurate diagnosis of breast cancer are still unresolved challenges. Today, a variety of imaging modalities and image-guided biopsy procedures exist to identify and characterize morphology and function of suspicious breast tissue. However, a clinically feasible solution for breast imaging, which is both highly sensitive and specific with respect to breast cancer, is still missing. As a consequence, unnecessary biopsies are taken and tumours frequently go undetected until a stage where therapy is costly or unsuccessful.

HAMAM (Highly accurate breast cancer diagnosis through integration of biological knowledge, novel imaging modalities, and modelling) project will tackle this challenge by providing a means to seamlessly integrate the available multi-modal images and the patient information on a single clinical workstation. Based on knowledge gained from a large multi-disciplinary database, populated within the scope of this project, suspicious breast tissue will be characterised and classified.

HAMAM will achieve this by:

  • Building the tools needed to integrate datasets / modalities into a single interface.
  • Providing pre processing / standardization tools that will allow for optimal comparison of disparate data
  • Building spatial correlation information datasets to allow for new similarity and multimodal tissue models. These will be key in the detection and diagnosis of breast cancer
  • Building in adaptability that allows for the integration of other sources of knowledge such as tumour models, genetic data, genotype, phenotype and standardised imaging.

The exact diagnosis of suspicious breast tissue is ambiguous in many cases. HAMAM will resolve this using the statistical knowledge extracted from the large case database. The clinical workstation will suggest additional image modalities that may be captured to optimally resolve these uncertainties. The workstation thus guides the clinician in establishing a patient specific optimal diagnosis. This ultimately leads to a more specific and individual diagnosis.

For further information, please visit:
http://www.hamam-project.eu

Project co-ordinator:
EIBIR gemeinnuetzige GmbH zur Foerderung der. Erforschung der biomedizinischen Bildgebung

Partners:

  • Boca Raton Community Hospital Inc (USA)
  • MeVis Research GmbH (Germany)
  • MeVis Medical Solutions AG (Germany)
  • University College London (United Kingdom)
  • Radboud Universiteit Nijmegen - Stichting Katholieke Universiteit (Netherlands)
  • Charité - Universitätsmedizin Berlin (Germany)
  • The University of Dundee (United Kingdom)
  • Eidgenössische Technische Hochschule Zürich (Switzerland)

Timetable: from 09/2008 - to 08/2011

Total cost: € 4.250.000

EC funding: € 3.100.000

Programme Acronym: FP7-ICT

Subprogramme Area: Virtual physiological human

Contract type: Collaborative project (generic)


Related news article:

Most Popular Now

Open Call HORIZON-MISS-2022-CANCER-01-04…

The overall goal of the Mission on Cancer[1] and the Europe's Beating Cancer Plan[2] includes a better quality of life for patients and their families living with, and after, cancer. Project...

Insilico Medicine Raises $60 Million in …

Insilico Medicine, a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, announced today that it has completed a $60 million Series D financing from a syndicate of global investors with...

Researchers Use AI to Predict Cancer Ris…

An artificial intelligence (AI) tool helps doctors predict the cancer risk in lung nodules seen on CT, according to a new study published in the journal Radiology. Pulmonary nodules appear as...

KTU Researchers Investigate the Links Be…

In recent years Alzheimer's disease has been on the rise throughout the world and is rarely diagnosed at an early stage when it can still be effectively controlled. Using artificial...

Speech Analysis App Predicts Worsening H…

A voice analysis app used by heart failure patients at home recognises fluid in the lungs three weeks before an unplanned hospitalisation or escalation in outpatient drug treatment. The late...

Screening for Diabetic Retinopathy Prove…

Both telemedicine and community screening for diabetic retinopathy (DR) in rural and urban settings are cost-effective in China, and telemedicine screening programs are more cost-effective, according to a study led...

Philips' Future Health Index 2022 Report…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the publication of its Future Health Index (FHI) 2022 report: 'Healthcare hits reset: Priorities shift as...

Researchers Develop Smartphone-Powered M…

A University of Minnesota Twin Cities research team has developed a new microfluidic chip for diagnosing diseases that uses a minimal number of components and can be powered wirelessly by...

App Detecting Jaundice in Babies a Succe…

A smartphone app that identifies severe jaundice in newborn babies by scanning their eyes could be a life-saver in areas that lack access to expensive screening devices, suggests a study...

InterSystems Wins Data Driven Product of…

InterSystems, a provider of next-generation solutions for enterprise digital transformation to help customers solve the most critical data challenges, has announced it received the prestigious Data Driven Product of the...

Siemens Healthineers Introduces Symbia P…

Siemens Healthineers introduces Symbia Pro.specta™, a single-photon emission computed tomography/computed tomography (SPECT/CT) system with CE Mark and Food and Drug Administration (FDA) clearance that has advanced SPECT and CT imaging...